Inflammatory bowel disease versus chronic enteropathy in dogs: are they one and the same?

J. R. S. Dandrieux

Faculty of Veterinary and Agricultural Sciences, Translational Research and Animal Clinical Trial Study (TRACTS) Group, The University of Melbourne, Werribee 3030, Victoria, Australia

The aim of this review is to discuss why “chronic enteropathy” might be a better term than “inflammatory bowel disease” in dogs, because the treatment and outcome of the disease is very different from that of inflammatory bowel disease in humans. The effect of food, antibiotics and immunosuppressant drugs on chronic enteropathy will be reviewed. New treatments under investigation will also be introduced. Although there are several studies evaluating treatment of chronic enteropathy in dogs, the quality and quantity of evidence supporting individual therapies remains scarce and more work is needed to improve management of this disease. Finally, new findings about dogs with chronic enteropathy complicated by protein-losing enteropathy will be discussed. Although prognosis for these dogs is poor, recent data might help improve their treatment.

CANINE CHRONIC ENTEROPATHY – IS IT THE SAME AS THE HUMAN DISEASE?

Inflammatory bowel disease (IBD) in humans includes two different chronic disorders characterised by inflammation of the intestinal wall: Crohn’s disease (CD) and ulcerative colitis (UC). Like humans, dogs also develop chronic (defined as longer than 3 weeks) enteropathy (CE) characterised by clinical signs such as vomiting, diarrhoea, borborygmus, hyporexia, abdominal pain, nausea and/or weight loss. CE is diagnosed after exclusion of extra-intestinal (such as hepatic, pancreatic or renal disease, hypoadrenocorticism and hypercalcaemia), infectious or parasitic diseases and intestinal disease of other aetiology [examples include mechanical obstruction from intussusception, foreign body or intestinal tumours (Simpson & Jergens 2011)]. One UK referral centre examining breed predisposition for CE reported increased odds ratios for developing disease in Weimaraner, rottweiler, German shepherd dog, Border collie and boxer breeds (Kathrani et al. 2011).

The current concept is that an idiopathic inflammation develops in a genetically predisposed patient, triggered by interactions between food components, environmental factors and intestinal microbiota (De Souza & Fiocchi 2016). The clinical signs result from uncontrolled inflammation. The aetiology of CE is suspected to be similar in dogs, as reviewed elsewhere by using the term IBD (Jergens & Simpson 2012).

However, there are some important differences between dogs and humans that need to be highlighted. Firstly, medical therapy is central to the management of the human conditions and is aimed at controlling the inflammation. Different types of immunosuppressant drugs are used alone or in combination to first induce and then maintain remission (Grevenitis et al. 2015). Previously, treatment response was defined by clinical response alone, but there is now evidence that achieving mucosal healing is important to reduce relapse rates in IBD patients (Dave & Loftus 2012). Current research is investigating whether more aggressive immunosuppression early in the disease course improves outcome (Grevenitis et al. 2015). In contrast, the majority of dogs will not require any treatment other than dietary modification. A further subset improves with antibiotic therapy and a small proportion will require immunosuppressant treatment, as reviewed elsewhere (Jergens & Simpson 2012). Figure 1 highlights the differences in stepwise application of treatment modalities between dogs and humans.
Watson a risk of recurrence of about 50% within 10 years (Annese with IBD will undergo surgery within 10 years of diagnosis, with need for surgery is extremely rare (Vester-Andersen pressant therapy this is still very different from dogs in which the might be reducing with a more widespread use of immunosuppressant treatment. For this reason, chronic enteropathy, although minimally invasive, is best reserved for animals that have failed diet and antibiotic trials. Exceptions include dogs with severe disease when there might not be enough time to conduct a treatment trial (e.g. PLE) or if there is a high suspicion of a neoplastic aetiology or infectious contribution to disease (e.g. granulomatous colitis in predisposed breeds).

Reported negative prognosis factors for dogs with CE include: high canine IBD activity index (CIBDAI), marked endoscopic disease in the duodenum, hypocobalaminaemia, hypoaalbuminaemia and hypovitaminosis D (Jergens et al. 2003, Craven et al. 2004, Allenspach et al. 2007, Titmarsh et al. 2015). Subsequently, a revised clinical score has been defined that takes into account some of these findings: the canine CE clinical activity index (CCECAI) (Allenspach et al. 2007). Both the CIBDAI and CCECAI have now been widely accepted and are used to assess clinical response to treatment.

As mentioned above, hypoaalbuminaemia is a negative prognostic factor and poor outcome has been reported for dogs with PLE. Furthermore, significantly lower vitamin D concentration in dogs with PLE has been reported although its relationship with survival has not been studied (Gow et al. 2011). Median survival times of less than 6 months or a 1-year survival of less than 50% have been reported (Littman et al. 2000, Dijkstra et al. 2010, Goodwin et al. 2011, Equilino et al. 2015). However, two abstracts report median survival times of over a year (Owens et al. 2011, Stroda et al. 2012). Long-term responders (12 out of 23 dogs with median survival times of 44 months) have also been reported amongst Yorkshire terriers treated with prednisolone in conjunction with diet and metronidazole (Simmeron et al. 2014). Typically, PLE dogs will often undergo endoscopy at time of diagnosis and aggressive treatment with both diet modification and early use of immunosuppressant treatment because of their guarded prognosis (Dosin & Lavoue 2011). However, some of these dogs might respond to diet alone as outlined later.

Secondly, it is estimated that 40 to 50% of human patients with IBD will undergo surgery within 10 years of diagnosis, with a risk of recurrence of about 50% within 10 years (Annese et al. 2016). Although there is some evidence that this percentage might be reducing with a more widespread use of immunosuppressant therapy this is still very different from dogs in which the need for surgery is extremely rare (Vester-Andersen et al. 2014, Watson et al. 2014).

### Why Use the Term “Chronic Enteropathy” Rather than “Inflammatory Bowel Disease” in Dogs?

Because of the differences between dogs and human in regards to treatment and the need for surgery to control clinical signs, it can be misleading to use the term “inflammatory bowel disease” in dogs. In effect, most dogs with this disease will not need immunosuppressant treatment. For this reason, chronic enteropathy is often used instead to describe dogs with chronic gastrointestinal signs. The advantages of using this term are:

1. It can be used for animals in which intestinal inflammation is suspected but has not been documented (i.e. no biopsies have been taken).
2. It does not infer which treatment will be needed to control clinical signs.

When the term inflammatory bowel disease is used for dogs, it typically implies that treatment trials with diet and subsequently antibiotics have failed, inflammation has been demonstrated and an immunosuppressant will be needed.

CE can further be subdivided retrospectively by response to treatment (Fig 2) into:

- **Food-responsive enteropathy: FRE.**
- **Antibiotic-responsive enteropathy: ARE.**
- **Immunosuppressant-responsive enteropathy: IRE** [dogs responding to steroids, usually reported as steroid-responsive diarrhoea (SRD), are included in this group].
- **Non-responsive enteropathy: NRE.**

Although diarrhoea has been used instead of enteropathy, the latter should be favoured as some dogs will present with signs other than diarrhoea.

In addition to this classification according to treatment response, dogs with loss of protein across the gut are typically grouped as protein-losing enteropathy (PLE), highlighting the more guarded prognosis of this particular form of CE compared to dogs with normal serum albumin concentration (Craven et al. 2004, Allenspach et al. 2007).

Knowing that a majority of dogs do not require immunosuppressant treatment, most clinicians will favour treatment trials first. Endoscopy or surgery is used to obtain biopsies in poor or non-responders to confirm the presence and type of intestinal inflammation and to rule out diffuse intestinal tumours such as lymphoma (Simpson & Jergens 2011). Histology has been shown not to help in differentiating FRE from ARE or IRE (Luckschan-der et al. 2006, Allenspach et al. 2007, Schreiner et al. 2008). For this reason endoscopy, although minimally invasive, is best reserved for animals that have failed diet and antibiotic trials.

Why Use the Term “Chronic Enteropathy” Rather than “Inflammatory Bowel Disease” in Dogs?

FIG 1. Stepwise medical treatment approach of inflammatory bowel disease in humans and chronic enteropathy in dogs. Treatment approach is different as a large number of dogs will respond to diet management alone whereas humans will need immune modulating treatment. 5-ASA: 5-aminosalicylic acid compounds. Biologic therapy includes tumour necrosis factor antagonists and anti-adhesion molecules.

<table>
<thead>
<tr>
<th>Humans</th>
<th>Dogs</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-ASA, antibiotics</td>
<td>Diet modification</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Antibiotics</td>
</tr>
<tr>
<td>Azathioprine, methotrexate, cyclosporine</td>
<td>Immunosuppressants</td>
</tr>
<tr>
<td>Biologic therapy</td>
<td></td>
</tr>
</tbody>
</table>

![Diagram](image-url)
FOOD-RESPONSIVE ENTEROPATHY IN DOGS WITH CE

A marked response to diet change alone in over 50% of CE dogs has been now shown in multiple referral centres around the world (Marks et al. 2002, Allenspach et al. 2007, 2016, Mandigers et al. 2010). Studies using diet as first-line therapy are summarised in Table 2 with very good long-term response (up to 3 years follow-up) in dogs fed different types of hydrolysed or novel antigen diets (Allenspach et al. 2007, Mandigers et al. 2010). In the study by Mandigers et al. (2010) the outcome was much better in comparison to an easily digestible, but non-exclusion diet (Table 2 for details). Most of these studies are prospective, although not blinded, and the high response rate and long-term response support diet as a first-line treatment. In several reports, FRE dogs are younger than IRE dogs and frequently present with signs of large bowel disease (Munster et al. 2006, Allenspach et al. 2007, 2016). Furthermore, they typically have lower CCECAI and normal albumin concentration compared to dogs with ARE or IRE (Allenspach et al. 2007, 2016).

It is unclear if there is a benefit of using hydrolysed diet (aiming at breaking down proteins into peptides to reduce antigenic reaction) over a novel antigen diet (new protein and carbohydrate source). More detailed information on the subject can be found in another review (Gaschen & Merchant 2011). Studies with both types of diet have had good outcomes (Table 2) and one study did not find a significant difference to clinical response between novel antigen or hydrolysed diet (Allenspach et al. 2016).

Clinically most FRE dogs respond within a few days but may take up to 14 days (Marks et al. 2002, Allenspach et al. 2007, 2016). This information needs to be relayed to the owner to increase owner compliance during the trial and improve success. This is the likely reason why nine dogs did respond to a stringent diet after referral although they had had previously unsuccessful diet trials (Mandigers et al. 2010).

Some dogs can be returned to their previous diet (from 31 to 75%) after a 12-week diet trial (Luckschander et al. 2006, Mandigers et al. 2010, Allenspach et al. 2016). There is no method currently to determine if a dog is going to relapse after challenge. For this reason, many owners elect to keep their dog on the new diet once the clinical signs are controlled. If the animal is given a home-cooked diet long-term, discussion with a nutritionist is needed to ensure correct balance between all essential nutrients. It is also worth considering measuring cobalamin concentration and supplement as necessary. Cobalamin concentration can also be used at a later stage for monitoring purposes. There is some evidence that cobalamin supplementation may improve clinical signs in hypocobalaminemic cats with CE and for this reason it might also be safer to supplement hypocobalaminemic dogs although there is currently no evidence to support a benefit in this species (Raux 2013).

As previously mentioned, the aim in humans with IBD has shifted from clinical resolution to histological resolution over the past years (Dave & Loftus 2012). One study examined the pathological changes in duodenal biopsies of 20 dogs with FRE before and after treatment (Walker et al. 2013). The authors examined histopathological, immunohistochemical and ultrastructural changes. There was a decrease in the mean mononuclear cell score (although not the overall histological score) and significant improvement in ultrastructural lesions within 6 weeks of diet change. This is the most in-depth study examining the effect of diet on pathological changes in the intestine and supports not only clinical resolution, but also brush border healing with diet change alone. Other studies have compared

Table 1. Levels of evidence for studies investigating the results of treatment

<table>
<thead>
<tr>
<th>Level</th>
<th>Type of Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>High quality randomised trial</td>
</tr>
<tr>
<td>II</td>
<td>Lesser-quality randomised trial</td>
</tr>
<tr>
<td>III</td>
<td>Case control study</td>
</tr>
<tr>
<td>IV</td>
<td>Retrospective comparative study</td>
</tr>
<tr>
<td>V</td>
<td>Case series</td>
</tr>
<tr>
<td></td>
<td>Expert opinion</td>
</tr>
</tbody>
</table>

Prospective studies are started before the first patient is enrolled whereas retrospective studies are started after the first patient was enrolled. Case series include dogs treated one way with no comparison group of patients treated another way. This table was adapted from Elsevier® recommendations (http://cdn.elsevier.com/promis_misc/623124los.pdf).
FOOD-RESPONSIVE ENTEROPATHY IN DOGS WITH PLE

The main histological findings in PLE dogs include lymphangiectasia (primary or secondary to inflammatory infiltration), inflammation, neoplasia and crypt abscesses (Dossin & Lavoué 2011). Diet trials with hydrolysed or novel antigen food as the sole treatment are seldom attempted because of the guarded prognosis and the risk of rapid deterioration. An exception might be in cases with primary lymphangiectasia (without an identified underlying process) in which good success has been reported with an ultra-low fat diet (Peterson & Willard 2003). However, lymph leakage can trigger intestinal inflammation and worsen the clinical picture with time (Van Kruiningen et al. 1984). For this reason, corticosteroids are often used concurrently until the clinical signs are controlled and so data on the effect of food alone are scarce. One retrospective study examined dogs with lymphangiectasia fed a low fat diet or ultra-low fat diet (Okanishi et al. 2014) together with prednisolone and metronidazole in dogs that did not respond or relapsed during corticosteroid tapering. No difference was seen in outcome between the two diets, with 79% of dogs improving during the 2-month study. Dogs fed the ultra-low fat diet had significantly higher albumin concentration 2 months after starting treatment. Although this study was not designed to look at the effect of diet alone, it supports the importance of dietary management to control clinical signs.

In summary, there is very little information published about dogs with PLE treated solely with diet change. However, it seems that some Yorkshire terriers will respond without adjunctive treatment for a long duration (Rudinsky et al. 2014), which might also be the case in other breeds. The central question is to determine how to select dogs for diet trial alone knowing that the prognosis for PLE is guarded and progression of disease can be rapid and fatal (Dossin & Lavoué 2011, Nakashima et al. 2015). My opinion is that diet trial might be considered in dogs with PLE if they are clinically well and have good appetite. If there is no improvement within a week (resolution of gastrointestinal signs and increase in albumin) or the animal deteriorates, intestinal biopsy would be strongly recommended if not already obtained. This helps to rule out neoplastic disease and to direct treatment as immunosuppressant drugs (with or without antibiotics) are likely to be required for ongoing management of these cases.

ANTIBIOTIC-RESPONSIVE ENTEROPATHY IN DOGS WITH CE

Antibiotics are often used as a second-line treatment if diet change has failed or only a partial response is observed. Oxytetracycline, metronidazole and tylosin are generally used (Table 3). The exact role of the antibiotic remains unclear. Possible effects include modification of the gut flora through antimicrobial effect and modulation of the immune-system. The reader is referred to
two recent reviews on the subject for further information (Hall 2011, Honneffer et al. 2014).

Granulomatous colitis of boxers is the only CE in which bacterial invasion of the intestinal wall has been documented with resolution of clinical signs apparent after clearance of bacteria (Hostutler et al. 2004, Mansfield et al. 2009). This disease has also been described in French bulldogs and a good response to enrofloxacin treatment is common, although resistance has been described (Craven et al. 2010, Manchester et al. 2013). For this reason, it is good practice to sample the colonic mucosa for culture to determine antibiotic susceptibility to guide treatment. Recently guidelines for the use of enrofloxacin for canine colitis have been published (Lechowski et al. 2013); treatment with 10-15 mg/kg every 24 hours orally has been suggested, with reassessment after 2 weeks and total treatment duration of 8 weeks in responders.

Dogs responding to antibiotics are usually younger dogs of large breed and German shepherd dogs are over-represented (Table 4) (German et al. 2001, Allenspach et al. 2016). In Finland, a tylosin response has been described in large dogs of middle-age, although an underlying infectious aetiology was not detected (Westermarck et al. 2005). After cessation of antibiotics, relapses are frequent, but control is typically achieved by reintroducing the antibiotic, whereas prevention with probiotic or control with prednisolone cannot be achieved. The effect of tylosin was confirmed in a double-blinded prospective clinical trial and a dosage as low as 5 mg/kg every 24 hours was found to be effective, with resolution of the diarrhoea within days (Kilpinen et al. 2011, 2014).

Antibiotic treatment is typically recommended for 4 to 6 weeks, but there is no published information to determine the optimal duration. A trial with a 1-week course of tylosin had similar success rates to a 6-week course, and there were similar relapse rates of 88% of dogs within 2 months and 86% within 30 days, respectively (Westermarck et al. 2005, Kilpinen et al. 2014). Based on these two studies, treatment duration did not seem to have an effect on rate or time to relapse. Another study raises concerns about long-term success in dogs treated with antibiotics: out of 33 dogs responding to metronidazole at a dosage of 15 mg/kg every 12 hours orally, all had relapsed after 6 to 12 months (Allenspach et al. 2016).

Response to both tylosin and metronidazole seems short-lived. This raises questions on how useful antibiotics truly are or whether concurrent treatments are needed to achieve long-term control and long-term use of antibiotics also raises the question of antibiotic resistance (Nitzan et al. 2016). Usually, if an antibiotic trial is started and not successful within 2 weeks, the animal needs to be re-assessed and addition of immunosuppressant drugs considered.

Lympho-plasmacytic inflammation is the most common histologic change in dogs with CE and does not predict to which treatment modality each dog will respond. In rare cases a neurophilic or granulomatous intestinal infiltrate is observed on histology (Simpson & Jergens 2011), suggesting that infectious (fungal or bacterial) aetiologies should be considered. Fluorescence in situ hybridisation (FISH) is a newer and very sensitive method to identify bacteria in tissue. FISH can be used on formalin-fixed tissue, which is an advantage over culture in identifying invasive bacteria. Finding bacteria in tissue is an indication for antibiotic treatment. Ideally, repeat biopsies can help to ensure resolution after treatment, although this is rarely performed in clinical practice.

In summary, the use of several antibiotics has been described in dogs with CE. With the exception of granulomatous colitis of boxers and French bulldogs, the efficacy of antibiotics is unclear.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Type</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytetracycline</td>
<td>Antibiotic</td>
<td>10 mg/kg, every 8 hours, orally</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Antibiotic</td>
<td>10 mg/kg, every 12 hours, orally</td>
</tr>
<tr>
<td>Tylosin</td>
<td>Antibiotic</td>
<td>20 mg/kg, every 8 to 12 hours, orally</td>
</tr>
<tr>
<td>Enrofloxacin†</td>
<td>Antibiotic</td>
<td>10-15 mg/kg, every 24 hours, orally</td>
</tr>
<tr>
<td>Prednisolone†</td>
<td>Corticosteroid</td>
<td>2 mg/kg or 30 mg/m², total dose, orally</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Cyclophilin binder</td>
<td>5 mg/kg, every 24 hours, orally</td>
</tr>
<tr>
<td>Chiorambucil§, Azathioprine¶</td>
<td>Alkylating agent, Purine antagonist</td>
<td>2-4 mg/m², every 24 hours, orally</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>Guanosine nucleotide synthesis inhibitor</td>
<td>10 mg/kg, every 12 hours, orally</td>
</tr>
</tbody>
</table>

**Table 3. Common drugs used in CE**

**Table 4. Response to antibiotic in dogs with CE and PLE**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Number of dogs *</th>
<th>Treatment success‡</th>
<th>Study duration</th>
<th>Evidence</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxytetracycline¹</td>
<td>12 (27)</td>
<td>44%</td>
<td>10 weeks</td>
<td>IV</td>
<td>German et al. (2001)</td>
</tr>
<tr>
<td>Tylosin²</td>
<td>9 (9)</td>
<td>100%</td>
<td>N/A</td>
<td>II (no blinding)</td>
<td>Westermarck et al. (2005)</td>
</tr>
<tr>
<td>Metronidazole⁴</td>
<td>33 (203)</td>
<td>0%</td>
<td>6 to 12 months</td>
<td>III</td>
<td>Allenspach et al. (2016)</td>
</tr>
<tr>
<td>PLE</td>
<td>Unknown</td>
<td>Rare</td>
<td>N/A</td>
<td>V</td>
<td>Dossin &amp; Lavoue (2011)</td>
</tr>
</tbody>
</table>

*Number of dogs on antibiotic trial, with total dogs in the study in brackets

†Dogs responding to antibiotic

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Number of dogs *</th>
<th>Treatment success‡</th>
<th>Study duration</th>
<th>Evidence</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxytetracycline¹</td>
<td>12 (27)</td>
<td>44%</td>
<td>10 weeks</td>
<td>IV</td>
<td>German et al. (2001)</td>
</tr>
<tr>
<td>Tylosin²</td>
<td>9 (9)</td>
<td>100%</td>
<td>N/A</td>
<td>II (no blinding)</td>
<td>Westermarck et al. (2005)</td>
</tr>
<tr>
<td>Metronidazole⁴</td>
<td>33 (203)</td>
<td>0%</td>
<td>6 to 12 months</td>
<td>III</td>
<td>Allenspach et al. (2016)</td>
</tr>
<tr>
<td>PLE</td>
<td>Unknown</td>
<td>Rare</td>
<td>N/A</td>
<td>V</td>
<td>Dossin &amp; Lavoue (2011)</td>
</tr>
</tbody>
</table>

*Number of dogs on antibiotic trial, with total dogs in the study in brackets

†Dogs responding to antibiotic
for most forms of CE and there is some evidence that responses are short-lived. If an infectious aetiology is suspected, FISH can be helpful to confirm it and, in positive cases, an antibiotic trial can be considered.

**ANTIBIOTIC-RESPONSIVE ENTEROPATHY IN DOGS WITH PLE**

No information is available on the use of antibiotics alone for treatment of PLE although few antibiotic-responsive cases have been reported (Dossin & Lavoue 2011). Some PLE dogs present with crypt abscesses, which has been shown to carry a poor prognosis (Willard et al. 2000, Stroda et al. 2012). Although, these changes could potentially represent bacterial infection, no evidence of bacterial association with crypt pathology in Yorkshire terriers was found using FISH (Craven et al. 2009). The question remains as to whether this sample was representative and if a bacterial aetiology might be present in other breeds.

As previously noted, FISH is worth considering if there is granulomatous or neutrophilic inflammation and antibiotic coverage might be considered whilst waiting on results in selected individuals.

In conclusion, there is currently very little evidence to determine if antibiotics are useful in PLE dogs with crypt abscesses and no information in dogs with other lesions. Future studies looking at bacterial association with PLE and treatment response are needed to assess whether antibiotics have a role in treating these affected dogs.

**IMMUNOSUPPRESSANT-RESPONSIVE ENTEROPATHY IN DOGS WITH CE**

Studies examining efficacy of immunosuppressant treatment in CE are summarised in Table 5 and usual dosages are shown in Table 3; more detailed information on immunosuppressant therapy can be found elsewhere (Viviano 2013). Prednisolone has been used extensively in dogs with CE (Jergens & Simpson 2012). Dogs responding to prednisolone are usually classified as steroid-responsive enteropathy (or diarrhoea) cases, which constitute a subgroup of dogs with IRE. Prednisolone is usually used in a step-up manner in dogs with mild to moderate disease (i.e. first diet trial, then antibiotic trial and then immunosuppressant drugs in the absence of prior response). If the disease is severe, or the dogs have PLE, the animal is usually treated with a combination of corticosteroids and diet with or without antibiotics and treatment is stepped down in responders or stepped up (change of dosage or drugs) in non-responders.

There are now several published studies in dogs using this step-up approach (Table 5). In earlier studies, a variety of immunosuppressant treatments were used and overall response was reported (an exhaustive list can be found in a previous review, Jergens & Simpson 2012). For the purpose of this current review, only studies using predominantly one immunosuppressant protocol, or comparing two protocols, are listed.

Immunosuppressant drugs used for CE include prednisolone, azathioprine, budesonide and cyclosporine. Most of the studies have a short follow-up (less than 6 months) and similar treatment success is reported (over 60%).

One study compared treatment with prednisolone versus budesonide, with similar remission rates (65%) in both groups over a 6-week period (Dye et al. 2013). One randomised-controlled study looked at the remission in dogs with CE - after exclusion of FRE and ARE – and treated with either prednisolone (n=25) or a combination of prednisolone and metronidazole (n=29) for 21 days (Jergens et al. 2010). The remission rate was over 80% in both groups (no difference), which does not support adding metronidazole to prednisolone for short-term control.

Two studies report the use of cyclosporine (same dose and formulation) in dogs not responding to prednisolone, with variable success (25% versus 79%). Only 2 dogs out of 8 with CE responded to cyclosporine in one study (Allenspach et al. 2007). Another study reports a better outcome with 11 dogs out of 14 responding; nine of these dogs had CE and five PLE and it is unreported to which category the non-responders belong (Allenspach et al. 2006).

How should “long-term success” for dogs on immunosuppressant therapy be defined? With prednisolone, amongst dogs classified as IRE only 48% of success over a 3-year period was reported in a study in Switzerland (n=21), and only 12.5% over a 6–12 month period in a recent British study (n=39) using several immunosuppressant protocols (Allenspach et al. 2007, 2016).

When using cyclosporine as a rescue protocol, one study showed more than 70% response for at least 6 months (mix of dogs with PLE and CE), whereas the other reported 25% response in dogs with CE over a 3-year follow-up (Allenspach et al. 2006, 2007). This suggests that response to cyclosporine is short-lived in a majority of dog. These results raise the question of long-term control in dogs with CE and highlight the need for more studies to address this question. Furthermore, not only remission duration, but differences between treatments need to be assessed. Cyclosporine might play a role as rescue treatment, but differences might exist between PLE and CE dogs, and long-term responses need to be further determined.

Interestingly although azathioprine is widely used in IBD in humans to maintain remission, no study is available in dogs with CE (Kim & Choe 2013). Occasional use amongst other drugs is reported, but no large case series is available (Willard et al. 2000, Craven et al. 2004, Munster et al. 2006, Allenspach et al. 2016).

Half the dogs with perianal fistulae in one study had distal colonic inflammation and it is uncertain whether these perianal fistulae are an extension of CE as is observed in people with UC (Jamieson et al. 2002). A prospective study performed in 13 German shepherd dogs and one Border collie with perianal fistulas, using a combination of diet, prednisolone and azathioprine, showed that 57% had complete remission after 16 weeks (Harkin et al. 2007). The use of different diets and the absence of a control group limit the interpretation. At this stage, information is lacking to determine the usefulness of azathioprine in CE. Anecdotally, other drugs used for CE include chlorambucil and mycophenolate.

In summary, short-term control of CE seems adequate with a variety of immunosuppressant drugs including prednisolone, azathioprine, budesonide and cyclosporine.
budesonide has not been studied and prednisolone treatment is interesting. A retrospective study looked into prognostic factors in dogs with small cell lymphoma (<500 days), whereas CE or IL had a significant negative prognostic factor (regardless of the group) with a median survival time of less than 200 days compared to over 1000 days in the absence of clonality. Finally, high CIBDAI score was predictive of mortality.

A positive test for clonality (i.e. PARR positive) is suggestive of neoplastic disease, but there are several difficulties with diagnosing intestinal small cell lymphoma in dogs:

- Clonality is sometimes found in inflammatory processes.
- Some cases highly suggestive for small cell lymphoma on histology are negative with PARR (Nakashima et al. 2015).
- PARR sensitivity depends on the methodology used (Takanosu & Kagawa 2015).

Although small cell lymphoma has been recognised in cats, it is not as well defined in dogs (Kiupel et al. 2011). One study identified three cases of small cell intestinal lymphoma out of 11 dogs when using histology and immunohistochemistry and another reported two cases out of 32 using a combination of histology, immunohistochemistry and PARR testing (Ozaki et al. 2006, Carrasco & Kagawa 2015). Overall, these findings suggest that a proportion of dogs with PLE are likely to have small cell lymphoma, although obtaining a final diagnosis is challenging.

One retrospective study compared PLE dogs treated with azathioprine or chlorambucil. Biopsies were obtained from all dogs.

**IMMUNOSUPPRESSANT-RESPONSIVE ENTEROPATHY IN DOGS WITH PLE**

As mentioned above, prognosis is guarded in dogs with PLE, although some Yorkshire terriers do respond well to corticosteroids, diet, and metronidazole (Simmerson et al. 2014). A recent interesting retrospective study looked into prognostic factors in dogs with PLE (Nakashima et al. 2015) and found very different median survival times depending on the final diagnosis. Ninety-two dogs were included and diagnosis was reached by combining histology, and clonality testing by polymerase chain reaction for antigen receptor rearrangement (PARR). Final diagnoses included: CE [including CE and intestinal lymphangiectasia (IL), n=62], small-cell intestinal lymphoma (n=19) and large-cell intestinal lymphoma (n=11). PLE dogs with large cell lymphoma had the worst prognosis (median survival time of <100 days), followed by small cell lymphoma (<500 days), whereas CE or IL had the best prognosis (>1000 days). Clonality was also found to be

![Image](https://example.com/image)

### Table 5. Response to immunosuppressant drugs in dogs with CE and PLE

<table>
<thead>
<tr>
<th>Drug</th>
<th>Number of dogs</th>
<th>Treatment success†</th>
<th>Follow-up</th>
<th>Evidence</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CE Diet+cyclosporine</td>
<td>14 (14)</td>
<td>79%</td>
<td>6 to 24 months</td>
<td>IV</td>
<td>Allenspach et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>Diet+metronidazole+prednisolone</td>
<td>16 (16)</td>
<td>100%</td>
<td>4 months</td>
<td>IV</td>
</tr>
<tr>
<td></td>
<td>Diet+prednisolone</td>
<td>21 (70)</td>
<td>48%</td>
<td>36 months</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>Metronidazole+prednisolone</td>
<td>29 (64)</td>
<td>83%</td>
<td>21 days</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>Prednisolone</td>
<td>25 (54)</td>
<td>88%</td>
<td>21 days</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>Budesonide</td>
<td>11 (11)</td>
<td>73%</td>
<td>30 days</td>
<td>IV</td>
</tr>
<tr>
<td></td>
<td>Prednisolone</td>
<td>16 (34)</td>
<td>69%</td>
<td>42 days</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Budesonide</td>
<td>18 (34)</td>
<td>78%</td>
<td>42 days</td>
<td>I</td>
</tr>
<tr>
<td>PLE Diet+cyclosporine</td>
<td>10 (70)</td>
<td>70%</td>
<td>36 months</td>
<td>II</td>
<td>Allenspach et al. (2007)</td>
</tr>
<tr>
<td></td>
<td>Diet+azathioprine+prednisolone</td>
<td>13 (27)</td>
<td>8%</td>
<td>See notes</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Diet+chlorambucil+prednisolone</td>
<td>14 (27)</td>
<td>71%</td>
<td>See notes</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Prednisolone</td>
<td>30 (30)</td>
<td>53%</td>
<td>4 to 80 months</td>
<td>IV</td>
</tr>
<tr>
<td></td>
<td>Prednisolone</td>
<td>62</td>
<td>N/A see notes</td>
<td>583 days</td>
<td>III</td>
</tr>
</tbody>
</table>

**CE chronic enteropathy, PLE protein-losing enteropathy**

Studies are grouped in dogs with CE or PLE. Study grouping dogs treated with different types of immunosuppressant as a single group have not been included in this table (such as Craven et al. 2004, Allenspach et al. 2016). (1) Cyclosporine was given at a dosage of 5mg/kg, every 24 hours, orally for 10 days in 14 dogs (of which five had PLE) instead of prednisolone in non-responders. Eleven dogs responded of which eight were discharged from cyclosporine after 10 weeks and remained in remission. Clinical response was seen within 2 weeks in most dogs and up to four in the remaining. (2) Prednisolone was started at 1mg/kg, every 12 hours, orally and reduced over 90 days to 0.5mg/kg, every 48 hours, orally. Metronidazole was given at 10mg/kg, every 12 hours, orally for 21 days. All dogs responded clinically, 75% had improvement in their endoscopic score, but no significant improvement was noted on histology after treatment. (3) Some of these dogs were also described by Allenspach et al. (2006) and Luckensdamer et al. (2006). Prednisolone treatment was started at 2mg/kg, every 24 hours, orally for 10 days and then tapered over 10 weeks. (4) From 11 dogs not responding to prednisolone in the study, eight were treated with cyclosporine. (5) Treatment with and without metronidazole were compared in this study. Prednisolone was given at 1mg/kg, every 12 hours, orally and metronidazole at 0.5mg/kg, every 12 hours, orally. There was no difference in the outcome between groups with and without metronidazole, but the follow-up was only 21 days. (6) Budesonide was used at 3mg/m2, every 24 hours, orally for 30 days. There was no report of corticosteroid side effects such as polydipsia, polyauria or polyphagia in these dogs. (7) Double-blinded, randomised-controlled trial with either prednisolone (1mg/kg, every 12 hours, orally for 3 weeks or budesonide (from 1mg, every 24 hours, orally for dogs 3 to 7kg up to 5mg, every 24 hours, orally for dogs more than 30kg). Systemic side effects consistent with corticosteroid treatment were seen in both groups. Similar remission rates were achieved in both groups. (8) These dogs were included in study 1 and did not respond to steroids. They were hypoalbuminaemic (<18g/L) and had ascites. They were treated with cyclosporine 5mg/kg, every 24 hours, orally for 10 weeks. (9) Median dosage was as follows for dogs treated with azathioprine: 2mg/kg, daily dose, orally of prednisolone and 1mg/kg, every 24 hours, orally of azathioprine. In dogs treated with chlorambucil: 1.7mg/kg, every 24 hours, orally of prednisolone and 4mg/m2, every 24 hours, orally of chlorambucil. Success was determined as time until primary treatment failure (i.e. either azathioprine or chlorambucil). Median duration of treatment with azathioprine was 30 days (2 to 599 days) and with chlorambucil 253 days (5 to 494 days). Cyclosporine was used as a rescue protocol in four dogs (three dogs treated with azathioprine and one with chlorambucil) with only one dog in the azathioprine group responding. (10) All dogs in this study were Yorkshire terriers. Dogs treated with metronidazole dosage of 1 to 2mg/kg, total dose per day, orally. One dog had azathioprine added after 4 weeks (complete resolution). Dog responding to treatment had a median survival time of 44 months (3 to 80) whereas non-responder had a mean survival time of 12 months (0 to 24 months). (11) Prednisolone dosage unknown. All dogs were treated with prednisolone and six with cyclosporine. Thirty-four dogs were diagnosed with CE and 28 with intestinal lymphangiectasia. Median survival time was over 1000 days.

† Dogs responding to treatment

*Number of dogs on immunosuppressant treatment and total dogs in the study in brackets
and were consistent with CE. None of these dogs were diagnosed with small cell lymphoma on histology, although no specific testing such as PARR or immunohistochemistry was performed. Dogs diagnosed in the first part of the study were treated with a combination of prednisolone and azathioprine (group A) and dogs diagnosed in the second part of the study were treated with prednisolone and chlorambucil (group C) (Dandrieux et al. 2013). Interestingly, group A was on their first treatment (median: 30 days [range 2 to 599]) for a shorter time than group C (253 days [5 to 494]). At the end of the study, median survival time for group A was 30 days, whereas it was not reached for group C. Even when all censored dogs were taken into account as treatment failures (to represent a worst-case scenario), 6-month survival rate was 15% in group A and 79% in group C. Although this study had several limitations (retrospective nature, historical case controls, absence of diet standardisation), the difference in outcome between groups was striking and warrants further prospective study.

Chlorambucil is the drug of choice for cats with small cell lymphoma, and associated with a median clinical remission of over 2 years (Stein et al. 2010). The findings of Nakashima et al. (2015) and the possible better outcome in PLE dogs treated with chlorambucil raises the question as to whether a proportion of PLE dogs have small cell lymphoma rather than CE. A prospective study is highly needed to explore this hypothesis further.

Cyclosporine has also been used in PLE dogs that do not respond to corticosteroid treatment, resulting in long-term (3 years) improvement in 7 out of 10 dogs (Allenspach et al. 2007). Another study reports the use of cyclosporine in some refractory cases with only 1 out of 4 dogs responding (Dandrieux et al. 2013).

In conclusion, various immunosuppressant drugs have been used in dogs with PLE. Cyclosporine holds some promise as a rescue agent in dogs that fail prednisolone therapy. Chlorambucil is also likely to have a role to play especially as there is now more evidence that dogs also suffer from small cell lymphoma, but achieving a definitive diagnosis is a first challenge to overcome. Further research is needed to compare different treatment modalities for PLE.

A proportion of Yorkshire terriers with PLE are long-term responders when treated with diet, prednisolone and metronidazole (Simmerson et al. 2014). However, some are also long-term responders with diet alone (Rudinsky et al. 2014). This highlights the need for further research to understand which dogs will benefit from dietary manipulation alone and which require more aggressive treatment.

**NON-RESPONSIVE ENTEROPATHY IN DOGS WITH CE OR PLE**

In most studies, there is no response to treatment in 15 to 40% of dogs in the short term. Furthermore, long-term response seems to be adequate only in FRE dogs, but not ARE and IRE dogs. This raises questions regarding adequacy of our current treatments (especially over the longer term) and the need for new treatments. Ideally, a better understanding of the different pathogenesis leading to CE is needed to obtain an accurate diagnosis and optimal treatment.

The first step for non-responders is to reconsider the diagnosis to ensure that no other disease process has been overlooked. Although some research has been done on gastrointestinal motility, there are few ways to assess it and treat it (Washabau 2003, Boilat et al. 2010) and, for this reason, motility issues are likely to be under-recognised and under-treated.

The microbiome has been shown to play a central role in several diseases and treatment to alter its constituents, using pre- and probiotics appears promising (Althani et al. 2015). Although few published studies are currently available in veterinary medicine, this domain will definitely further develop. One recent open-label study compared short-term treatment with a probiotic (D-VSL#3) versus metronidazole and prednisolone in dogs with CE (Rossi et al. 2014). Although both groups responded to treatment, there was some evidence of a possible anti-inflammatory effect after treatment with D-VSL#3 (increase in FoxP3 and TGF-β+ cells), which was not present in dogs treated with prednisolone. This difference is very intriguing and highlights the need for further research. The reader is directed to recent reviews for more information (Grzeskowiak et al. 2015, Schmitz & Suchodolski 2016). It is unclear if this type of treatment will be used as an adjunctive or a replacement for current therapies.

Another promising technique to alter the intestinal flora is fecal transplantation (Brandt & Aroniadis 2013). The techniques consist of administering fecal material from a "healthy" donor to a patient. Its utility has been accepted in human patients with recurrent Clostridium difficile infection, but it might also be successful for other types of GI diseases. Central to the technique is to identify the right diseases and the right donors. There is currently very little information on this topic published in veterinary medicine, although the limited information suggests alteration of the microbial flora and a good outcome is achievable (Wesse et al. 2013). Hopefully more studies will become available in the near future to assess the utility of fecal transplantation in dogs. A recent comment has been published on key aspects for this technique, which will help designing future studies (Chaitman et al. 2016). Another therapy attracting a lot of attention currently is the use of mesenchymal stem cells for the treatment of inflammatory conditions such as CE (Gattegno-Ho et al. 2012). Their effects rely on regenerative as well as anti-inflammatory properties. One study has been published in dogs with NRE, with 8 out 11 dogs in remission (decrease in CIBDAl of more than 75%) at the end of the study (Perez-Merino et al. 2015). Although this study was short (42 days), these are very promising results and further research in this domain is expected.

Finally, hypovitaminosis D has been reported in dogs with CE and with PLE (Gow et al. 2011, Titmarsh et al. 2015) and been shown to be a negative prognostic factor in dogs with CE (Titmarsh et al. 2015). There is currently no information regarding vitamin D supplementation or what the impact of this would be in deficient cases.
Table 6. Summary

<table>
<thead>
<tr>
<th>CE</th>
<th>FRE</th>
<th>ARE</th>
<th>IRE</th>
<th>PLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Term does not infer which treatment will be needed to control clinical signs.</td>
<td>• A majority of dogs respond long-term to diet trials with hydrolysed or novel antigen diets.</td>
<td>• GCB is the only CE with confirmed bacterial aetiology.</td>
<td>• Short-term control can be achieved with budesonide or prednisolone in a majority of cases.</td>
<td>• Some dogs seem to respond to diet alone: if considered, use only in dogs with minimal clinical signs and good appetite.</td>
</tr>
<tr>
<td>• CE can be used for dogs without a histological diagnosis.</td>
<td>• Response is typically very fast (within a few days to two weeks).</td>
<td>• FISH can be useful to document bacterial involvement.</td>
<td>• Cyclosporine can be used in corticosteroid non-responders, although the response might be short-lived.</td>
<td>• A proportion of dogs might have intestinal small cell lymphoma and benefit from more aggressive treatment.</td>
</tr>
<tr>
<td></td>
<td>• After resolution of clinical signs, some dogs might be able to resume their previous diet (trial and error).</td>
<td>• Effects of antibiotic therapy seem to be short-lived in dogs with CE other than GCB.</td>
<td></td>
<td>• If intestinal small cell lymphoma is suspected, immunohistochemistry and PARR can help to confirm.</td>
</tr>
</tbody>
</table>

CE in dogs encompasses different entities defined by response to medical treatment (Table 6). In contrast, IBD in humans is a disease that requires immunosuppressant drugs and, oftentimes, surgery. When the term IBD is used for dogs, it implies a thorough work-up to exclude extra-intestinal diseases and intestinal diseases such as parasitism, failure to respond to dietary and antibiotic trial, confirmed inflammation on intestinal biopsies, and requirement for immune-modulators. Because some of these steps are often missing, “chronic enteropathy” can be used as an alternative umbrella term. Dogs can then be classified by their response to different trials into the sub-divisions of FRE, ARE, IRE and NRE.

It is known that a majority of dogs respond to diet alone in referral centres and it should be considered as the first-line treatment in dogs with mild to moderate disease. Although response to diet was recognised about 10 years ago, it is interesting to note that even in recent studies, most dogs referred for CE are ultimately diagnosed with FRE. This highlights the importance of: (1) performing a proper diet trial prior to referral and (2) ensuring owner compliance by explaining the reason and duration of the trial. It is likely that compliance is enhanced in owners agreeing to referral. However, hopefully more clients in general practice can be persuaded to comply with a strict diet trial after highlighting the high prevalence of FRE. Compliance might increase if owners clearly understand that no other treatment than a food change is needed in a majority of dogs to reach long-term resolution (clinically and ultrastructurally).

If an immunosuppressant is needed, both prednisolone and budesonide have shown good short-term success. It is worth noting that systemic corticosteroid side effects have also been seen with budesonide. There is some evidence to suggest that cyclosporine is a good choice in a proportion of non-responders. In any case, long-term response to immunosuppressant remains inadequate and further research is needed to improve the outcome for these dogs.

PLE dogs present another challenge, with fewer studies available to guide treatment. New insight suggests that some dogs will respond to food alone, although the challenge is to select the right candidate for a diet trial. It is likely to be an adequate choice for at least a short duration (i.e. 1 week) in dogs that are clinically well and with good appetite. In the absence of response, treatment should be escalated. There is also building evidence that some PLE dogs have intestinal small cell lymphoma. Improved diagnostic tools are needed to identify these cases early to implement more aggressive treatment, which might include chlorambucil as has been described in cats.

There is a paucity of well-designed studies looking at the optimal treatment for dogs with CE. These are needed to help the clinician decide how to best manage these cases. Long-term control of dogs with CE seems adequate for FRE, but not for ARE and IRE. Ideally, more prospective studies with both short and long-term follow-up will be conducted to identify the most successful treatments for each type of CE and further define our management of this challenging disease.

Acknowledgements

The author would like to thank Drs Josephine Dandrieux and Lauren Lacorcia for critical review of this manuscript. Grant: Melbourne International Research Scholarship (MIRS), Melbourne International Fee Remission (MIFR).
Conflict of interest
The author of this article has no personal or financial relationship with other people or organisations that could inappropriately influence or bias the content of the paper.

References


